вход по аккаунту


S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin.

код для вставкиСкачать
Vol. 58, No. 12, December 2008, pp 3924–3931
DOI 10.1002/art.24137
© 2008, American College of Rheumatology
S100A12 Is a Novel Molecular Marker Differentiating
Systemic-Onset Juvenile Idiopathic Arthritis From Other
Causes of Fever of Unknown Origin
Helmut Wittkowski,1 Michael Frosch,1 Nico Wulffraat,2 Raphaela Goldbach-Mansky,3
Tilmann Kallinich,4 Jasmin Kuemmerle-Deschner,5 Michael C. Frühwald,1 Sandra Dassmann,1
Tuyet-Hang Pham,3 Johannes Roth,1 and Dirk Foell1
mia [ALL], 5 with acute myeloblastic leukemia [AML],
and 83 with systemic infections). All samples were
collected at the time of presentation, before the initiation of any treatment, and concentrations of S100A12
were determined by enzyme-linked immunosorbent assay.
Results. The mean ⴞ 95% confidence interval
serum levels of S100A12 were as follows: in patients with
JIA, 7,190 ⴞ 2,690 ng/ml; in patients with FMF, 6,720 ⴞ
4,960 ng/ml; in patients with NOMID, 720 ⴞ 450 ng/ml;
in patients with MWS, 150 ⴞ 60 ng/ml; in patients with
infections, 470 ⴞ 160 ng/ml; in patients with ALL, 130 ⴞ
80 ng/ml; in patients with AML, 45 ⴞ 60 ng/ml; in
healthy control subjects, 50 ⴞ 10 ng/ml. The sensitivity
and specificity of S100A12 to distinguish between
systemic-onset JIA and infections were 66% and 94%,
Conclusion. S100A12, a marker of granulocyte
activation, is highly overexpressed in patients with
systemic-onset JIA or FMF, which may point to as-yet
unknown common inflammatory mechanisms in these
diseases. The measurement of S100A12 serum levels
may provide a valuable diagnostic tool in the evaluation
of FUO.
Objective. Fever of unknown origin (FUO) in
children presents a diagnostic challenge. The differential diagnosis includes systemic-onset juvenile idiopathic arthritis (JIA), an autoinflammatory syndrome
associated with activation of phagocytic cells that, at
presentation, is difficult to differentiate from severe
systemic infections. The aim of this study was to investigate whether serum concentrations of the phagocytic
proinflammatory protein S100A12 may help in deciding
whether to treat patients with FUO with antibiotics or
immunosuppressive agents.
Methods. Serum samples were obtained from 45
healthy control subjects and from 240 patients (60 with
systemic-onset JIA, 17 with familial Mediterranean
fever [FMF], 18 with neonatal-onset multisystem inflammatory disease [NOMID], 17 with Muckle-Wells
syndrome [MWS], 40 with acute lymphoblastic leukeSupported by grants from the Interdisciplinary Centre for
Clinical Research at the University of Muenster (project Foe2/005/06)
and the Deutsche Forschungsgemeinschaft (DFG project FO 354/2-2).
Helmut Wittkowski, MD, Michael Frosch, MD, Michael C.
Frühwald, MD, PhD, Sandra Dassmann, MD, Johannes Roth, MD,
Dirk Foell, MD: University Hospital Muenster, and University of
Muenster, Muenster, Germany; 2Nico Wulffraat, MD: Wilhelmina
Children’s Hospital, and University Medical Centre, Utrecht, The
Netherlands; 3Raphaela Goldbach-Mansky, MD, MHS, Tuyet-Hang
Pham, MT: National Institute of Arthritis and Musculoskeletal and
Skin Diseases, NIH, Bethesda, Maryland; 4Tilmann Kallinich, MD:
Charité Children’s Hospital, Berlin, Germany; 5Jasmin KuemmerleDeschner, MD: University Children’s Hospital, and University of
Tuebingen, Tuebingen, Germany.
Dr. Roth has applied for a patent for a method of diagnosing
inflammatory diseases using calgranulin C (US patent application
Address correspondence and reprint requests to Johannes
Roth, MD, Department of Pediatrics, University of Muenster, AlbertSchweitzer-Strasse 33, D-48149 Muenster, Germany. E-mail:
Submitted for publication February 8, 2008; accepted in
revised form September 5, 2008.
Fever of unknown origin (FUO) frequently presents a diagnostic challenge in the pediatric population,
despite recent advances in terms of diagnostic tools and
techniques (1,2). FUO can be the primary manifestation
of a broad spectrum of diseases, but the main causes of
FUO in children are infections. Substantial progress has
been achieved in the diagnosis of infectious and other
causes of fever, due to new developments in nuclear
medicine techniques, and genetic testing for diagnosing
rare hereditary autoinflammatory conditions associated
with fever. Nevertheless, there is no diagnostic checklist
for children, and up to 200 conditions causing fever must
be ruled out, often leading to prolonged periods of
hospitalization and treatment attempts that include various antibiotic regimens (3,4).
Systemic-onset juvenile idiopathic arthritis (JIA,
Still’s disease; OMIM 604302) is important in the differential diagnosis of FUO in children. Systemic-onset JIA
is an aggressive autoinflammatory disease that resembles sepsis (5–7). Although the pathogenesis of systemiconset JIA remains poorly understood, overwhelming
activation of the innate immune system due to an
imbalance between proinflammatory cytokines and immune deactivators without evidence of involvement of
the adaptive immune responses is observed in these
patients (8,9). Unfortunately, characteristic signs of arthritis often do not develop before the later course of
this disease; therefore, at the initial presentation, the
nonspecific pattern of inflammation in patients with
systemic-onset JIA cannot be differentiated from systemic infections by clinical or laboratory parameters,
and suitable biomarkers are missing. In many cases, an
empirical antibiotic treatment is initiated before a definitive diagnosis is made. This clinical uncertainty impedes
early initiation of appropriate antiinflammatory therapy
In a previous study, we observed high concentrations of S100A12 in serum from patients with systemiconset JIA (11). S100A12 is a calcium-binding protein
expressed and secreted by activated phagocytes. Recently, S100A12 was assigned to the family of damageassociated molecular pattern molecules, which represent
endogenous ligands of pattern recognition receptors
(12). S100A12 has proinflammatory properties in vitro
at concentrations found in systemic-onset JIA serum in
vivo (11,13). It is mainly expressed in granulocytes and
binds to the receptor for advanced glycation end products (14). Activation of this receptor induces proinflammatory responses in leukocytes and endothelial cells via
NF-␬B (15,16).
S100A12 is a useful marker protein for monitoring disease activity in several inflammatory diseases
(17). In the present study, we assessed the diagnostic
value of S100A12 serum levels in differentiating between
systemic-onset JIA in the initial disease phase versus
acute systemic infections and childhood leukemic malignancies as the most relevant differential diagnoses.
Additionally, we included sera from patients with other
hereditary interleukin-1 (IL-1)–driven diseases, including familial Mediterranean fever (FMF; OMIM 249100),
neonatal-onset multisystem inflammatory disease (NO-
MID; OMIM 607115), and Muckle-Wells syndrome
(MWS; OMIM 191900). All of these disorders typically
present as FUO. To the best of our knowledge, this is
the largest study of a biomarker in FUO to date.
Healthy control subjects. Normal S100A12 levels were
determined in 45 healthy control subjects, all of whom gave
informed consent. These individuals without signs of inflammation underwent a routine evaluation at the University
Children’s Hospital Muenster or volunteered in our laboratory. There were no significant differences between patients
and control subjects with regard to age or sex distribution.
Patients. The study was designed as a prospective trial
in which data collection was planned before the measurements
of diagnostic accuracy were performed. The study group
comprised patients with systemic-onset JIA, FMF, NOMID,
MWS, acute lymphoblastic leukemia (ALL), or acute myeloblastic leukemia (AML) and patients with systemic infections.
Patients were included between July 1998 and February 2007
and were from the University Children’s Hospital Muenster,
the Wilhelmina Children’s Hospital, Utrecht, the National
Institute of Arthritis and Musculoskeletal and Skin Diseases,
Bethesda, the Charité Children’s Hospital, Berlin, and the
University Children’s Hospital Tuebingen. The cohort of NOMID patients from Bethesda was the only patient group
analyzed in a retrospective manner, because patient samples
existed before the decision to analyze S100A12 was made.
Recruitment of the patients required verification of the underlying disease and proinflammatory active disease, as defined
below. The study was approved by the institutional ethics
committee at each center, and informed consent was obtained
from patients or their legal guardians.
Patients with systemic-onset JIA fulfilled the criteria of
the International League of Associations for Rheumatology
(ILAR), with symptoms of quotidian fever, arthritis, rash,
hepatomegaly, splenomegaly, or serositis (18). Clinical disease
activity was determined on the basis of the core set criteria for
JIA (19,20). Inclusion criteria for patients with clinical and
laboratory signs of severe systemic infections were a C-reactive
protein (CRP) level ⬎50 mg/liter and fever ⬎38.5°C.
Laboratory parameters. The white blood cell count
(cells/␮l), the absolute neutrophil count (cells/␮l), the erythrocyte sedimentation rate (ESR; mm/hour), and the CRP
concentration (mg/liter) were determined as serum markers of
Determination of concentrations of S100A12 by sandwich enzyme-linked immunosorbent assay (ELISA). Serum
samples were centrifuged within 2 hours after acquisition and
frozen at ⫺80°C until measured. Concentrations of S100A12
were determined by a double sandwich ELISA system established in our laboratory, as previously described (21). Antibodies and protein standards of recombinant S100A12 (0.25–250
ng/ml) were generated as reported previously (22). All samples
were diluted to the linear range of the assay. The interassay
and intraassay coefficients of variation were 12.1% and 4.8%,
respectively (23). The readers of the laboratory assays were
Table 1. Characteristics of the patients and healthy controls*
Systemic JIA
(n ⫽ 60)
(n ⫽ 17)
(n ⫽ 83)
(n ⫽ 18)
(n ⫽ 17)
(n ⫽ 40)
(n ⫽ 5)
(n ⫽ 45)
Age, median (range) 9.1 (1.8–18.1) 11.7 (3.8–18.6) 8.1 (1.2–33.2) 11.0 (4.1–32.0) 34.6 (5.0–73.2) 6.2 (0.9–14.9) 11.0 (0.7–16.9) 16 (1.2–34.3)
No. men/no. women
Leukocytes, ␮l
16,120 ⫾ 2,220
13,300 ⫾ 1,200 17,200 ⫾ 3,600
38,290 ⫾ 36,400 33,120 ⫾ 71,800 6,700 ⫾ 1,100
ESR, mm/hour
76 ⫾ 23
38 ⫾ 21
40 ⫾ 18
60 ⫾ 16
24 ⫾ 9
75 ⫾ 33
11 ⫾ 8
CRP, mg/liter
84 ⫾ 19
40 ⫾ 29
111 ⫾ 11
68 ⫾ 19
18 ⫾ 9
28 ⫾ 17
17 ⫾ 50
S100A12, ng/ml
7,190 ⫾ 2,690 6,720 ⫾ 4,960
470 ⫾ 160
720 ⫾ 450
150 ⫾ 60
130 ⫾ 80
45 ⫾ 60
50 ⫾ 10
* Except where indicated otherwise, values are the mean ⫾ 95% confidence interval. JIA ⫽ juvenile idiopathic arthritis; FMF ⫽ familial
Mediterranean fever; NOMID ⫽ neonatal-onset multisystem inflammatory disease; MWS ⫽ Muckle-Wells syndrome; ALL ⫽ acute lymphoblastic
leukemia; AML ⫽ acute myeloblastic leukemia; ND ⫽ not determined; ESR ⫽ erythrocyte sedimentation rate; CRP ⫽ C-reactive protein.
blinded to the diagnosis. For comparison with earlier studies,
internal control sera were included in all ELISA studies.
Statistical analysis. Analysis of variance was used to
analyze differences between subgroups of patients or control
subjects. Confirmed differences were tested for statistical
significance using subsequent selective post hoc testing as
described by Dunnett and Tamhane. Rank differences were
analyzed using the Mann-Whitney U test. Receiver operating
characteristic (ROC) curves were plotted to determine the
accuracy of inflammation marker measurements as a diagnostic test and for the calculation of different cutoff values with
different sensitivities and specificities. Statistical analyses were
performed with SPSS for Windows, version 13.0 (Stata Corporation, College Station, TX). Except where indicated otherwise, data are expressed as the mean ⫾ 95% confidence
interval (95% CI).
Patients with systemic-onset JIA, FMF, MWS,
NOMID, or systemic infections. A total of 240 patients
were included. Patients occasionally took antipyretic
drugs, and other concomitant medications used by the
patients are listed where applicable. The characteristics
of the patients are shown in Table 1.
In total, 60 patients with systemic-onset JIA were
enrolled. In all 60 patients, the diagnosis was determined
by experienced pediatric rheumatologists (MF, NW, JR)
and classified according to the ILAR criteria. Three
patients were between the ages of 16 years and 18 years
and in this respect did not meet the ILAR criteria but
rather represented adult-onset Still’s disease. Serum
samples were obtained at the initial presentation, during
episodes of fever and high disease activity and before the
initiation of specific therapy. Patients were enrolled in
the centers at Muenster and Utrecht only and were
followed up until confirmation of the diagnosis and
initiation of appropriate antiinflammatory treatment.
Among the 17 patients with FMF who were
included, 5 had mutations in the MEFV gene in M694V/
M694V, 2 had mutations in M680I/M680I, 1 had mutations in S242R/M694V, 6 had mutations in M680I/
M694V, 1 had mutations in M694V/R761H, and 2
patients had no mutations. Five patients who did not
receive colchicine treatment had active disease and, at
the time of presentation, had at least 1 of the following
clinical manifestations: serositis, arthritis, fever, or rash.
The 12 patients who were receiving colchicine had minor
disease flares, with elevated levels of acute-phase reactants or symptoms related to FMF, such as abdominal
pain, arthralgia, or rash.
We also included 17 patients with MWS, from 7
families. Thirteen patients had heterozygous E311K
mutations and 3 had heterozygous V198M mutations in
the NLRP3 gene. At the time of sample acquisition,
patients presented with at least 2 of the following clinical
manifestations: sensorineural hearing loss, abdominal
pain, headaches, conjunctivitis, serositis, arthritis, fever,
rash, or clinical signs of inflammation, including high
levels of markers of inflammation, such as the CRP
concentration and the ESR. At that time, patients did
not receive antiinflammatory treatment.
Of 18 patients with NOMID, 12 had proven
mutations in exon 3 of the CIAS1 gene (24). Patients
presented with active disease, showing at least 2 of the
following clinical manifestations: urticarial rash, central
nervous system involvement (e.g., papilledema, pleocytosis in the cerebrospinal fluid, and sensorineural hearing loss), or epiphyseal or patellar overgrowth on radiography. At the time of sampling, all patients had active
inflammatory disease despite receiving antiinflammatory drug treatment, but none of the patients was treated
with recombinant IL-1 receptor antagonist (IL-1Ra).
Figure 1. Serum concentrations of S100A12 (A) and C-reactive protein (CRP) (B) in patients with systemic-onset juvenile idiopathic arthritis
(SOJIA), familial Mediterranean fever (FMF), systemic infections, neonatal-onset multisystem inflammatory disease (NOMID), Muckle-Wells
syndrome (MWS), acute lymphoblastic leukemia (ALL), or acute myeloblastic leukemia (AML), and in a group of healthy control subjects. Data
are presented as box plots, where the boxes represent the 25th to 75th percentiles, the thin lines within the boxes represent the median, the thick
lines within the boxes represent the mean, and the lines outside the boxes represent the 10th and 90th percentiles. CRP levels did not differ
significantly between patients with systemic-onset JIA and those with systemic infections. Healthy control subjects had CRP levels ⬍5 mg/liter.
ⴱ ⫽ P ⬍ 0.05; ⴱⴱ ⫽ P ⬍ 0.01; ⴱⴱⴱ ⫽ P ⬍ 0.001, versus systemic-onset JIA.
Of 83 patients with severe systemic infections, 64
had documented bacterial infections (38 had pneumonia, 8 had urinary tract infections, 3 had gastrointestinal
tract infections, 2 had osteomyelitis, 2 had soft tissue
infections, 6 had sepsis, 3 had peritonitis, and 2 had
appendicitis). In 19 patients, the infection was classified
to be of viral origin (14 had respiratory tract infections,
4 had gastrointestinal tract infections, and 1 patient had
Epstein-Barr virus infection). All serum samples were
obtained prior to the start of antibiotic treatment.
Forty-five patients with hematologic malignancies were included, 40 patients had ALL, and 5 patients
had AML. Serum samples were obtained at the time of
the initial manifestations, before initiation of therapy.
No differentiation between systemic-onset JIA
and systemic infections, using classic markers of inflammation. The mean ⫾ 95% CI serum CRP levels in
patients with systemic-onset JIA (84 ⫾ 19 mg/liter) were
not significantly different from those in patients with
severe infections (111 ⫾ 11 mg/liter; P ⫽ 0.297), NOMID (68 ⫾ 19 mg/liter; P ⫽ 0.99), or FMF (40 ⫾ 29
mg/liter; P ⫽ 0.253) but were significantly different from
those in patients with AML (17 ⫾ 50 mg/liter; P ⬍ 0.01),
patients with ALL (28 ⫾ 17 mg/liter; P ⫽ 0.049), and
patients with MWS (18 ⫾ 9 mg/liter; P ⬍ 0.001) (Table
1 and Figure 1B). CRP levels in patients with FMF were
significantly lower than those in patients with systemic
infections (P ⫽ 0.004) but did not differ significantly
from those in patients with NOMID (P ⫽ 0.892), MWS
(P ⫽ 0.948), or ALL (P ⫽ 1.0). Determination of the
diagnostic accuracy of the CRP concentration in the
ROC analysis revealed an area under the curve value of
0.313 ⫾ 0.103 (mean ⫾ 95% CI), confirming that CRP
values were not reliable markers for the diagnosis of
systemic-onset JIA (Figure 2).
ESRs were significantly elevated in patients with
systemic-onset JIA (P ⫽ 0.002) and those with NOMID
(P ⫽ 0.002) when compared with the ESRs in patients
with MWS, but these rates did not significantly differ
between each other nor when compared with those in
patients with infections, FMF, or ALL.
Significantly different levels of S100A12 in patients with systemic-onset JIA or FMF compared with
those in patients with severe infections, other autoinflammatory syndromes, or hematologic leukemias. The
mean ⫾ 95% CI serum S100A12 levels in patients with
active systemic-onset JIA (7,190 ⫾ 2,690 ng/ml) were
⬃145-fold higher than those in healthy control subjects
(50 ⫾ 10 ng/ml; P ⬍ 0.001) and were also significantly
higher than those in patients with systemic infections
(470 ⫾ 160 ng/ml; P ⬍ 0.001), NOMID (720 ⫾ 450
ng/ml; P ⬍ 0.001), MWS (150 ⫾ 60 ng/ml; P ⬍ 0.001),
ALL (130 ⫾ 80 ng/ml; P ⬍ 0.001), or AML (45 ⫾ 60
ng/ml; P ⬍ 0.001) (Table 1 and Figure 1A). Serum
concentrations of S100A12 in patients with FMF were
similar to those in patients with systemic-onset JIA
(6,720 ⫾ 4,960 ng/ml) and were ⬃135-fold higher than
those in healthy control subjects (P ⬍ 0.001). There was
no statistical difference between patients with systemiconset JIA and those with FMF concerning S100A12
serum levels (P ⫽ 1.0). When comparing FMF with
systemic infections, NOMID, MWS, ALL, and AML,
differences were significant in group-to-group analysis
by Mann-Whitney U test but not in the selective post hoc
test described by Dunnett and Tamhane, probably due
to the low number of patients with FMF.
S100A12 serum concentrations differentiate very
well between systemic-onset JIA and other causes of
FUO besides FMF, as confirmed by ROC analyses. The
areas under the curve for S100A12 were 0.881 ⫾ 0.078
(mean ⫾ 95% CI) in the differentiation between
systemic-onset JIA and systemic infections (Figure 2)
and 0.866 ⫾ 0.084 between systemic-onset JIA and
NOMID. At a cutoff concentration of 1,400 ng/ml,
S100A12 revealed a sensitivity of 66% and a specificity
Table 2. Differentiation of systemic JIA versus bacterial infections
and NOMID using the S100A12 concentration at various cutoffs*
Parameter (mean ⫾ 95%
confidence interval AUC),
S100A12 cutoff
Systemic JIA vs. infections
(0.881 ⫾ 0.078)
800 ng/ml
1,400 ng/ml
2,750 ng/ml
Systemic JIA vs. NOMID
(0.866 ⫾ 0.084)
800 ng/ml
1,400 ng/ml
2,750 ng/ml
Systemic JIA vs. MWS
(0.972 ⫾ 0.031)
1,000 ng/ml
Systemic JIA vs. ALL
(0.981 ⫾ 0.024)
1,000 ng/ml
Systemic JIA vs. AML
(1.000 ⫾ 0.0)
150 ng/ml
Systemic JIA vs. controls
(0.994 ⫾ 0.012)
150 ng/ml
Sensitivity, Specificity, Positive
* The range of the positive likelihood ratio (LR) is 0 to infinity. JIA ⫽
juvenile idiopathic arthritis; NOMID ⫽ neonatal-onset multisystem
inflammatory disease; AUC ⫽ area under the curve; MWS ⫽ MuckleWells syndrome; NA ⫽ not applicable; ALL ⫽ acute lymphoblastic
leukemia; AML ⫽ acute myeloblastic leukemia.
of 94% to distinguish systemic-onset JIA from systemic
infections. The corresponding positive likelihood ratio
(LR) was 11.0. To distinguish between systemic-onset
JIA and NOMID at a cutoff concentration of 1,400
ng/ml, S100A12 sensitivity was 66% and specificity was
89%, with a corresponding positive LR of 6.0. To
distinguish between systemic-onset JIA and MWS or
ALL at a cutoff concentration of 1,000 ng/ml, the
sensitivity was 78% and specificity was 100% in each
case (Table 2).
Figure 2. Receiver operating characteristic curve analysis of S100A12
and C-reactive protein (CRP) serum levels, for the differentiation of
systemic-onset juvenile idiopathic arthritis and systemic infections. The
mean ⫾ 95% confidence interval area under the curve was 0.881 ⫾
0.078 for S100A12 and 0.313 ⫾ 0.103 for CRP.
The main differential diagnoses of FUO are as
follows (in order of importance): infections without
focus, autoinflammatory/rheumatic diseases, and malignancies. For systemic-onset JIA, as a prototypic autoinflammatory disease, no laboratory test is available to
ascertain the diagnosis, and specific clinical signs (i.e.,
arthritis) often develop later in the course of the disease.
Typically, patients present with a marked elevation in
the level of acute-phase reactants and a clinical course
resembling sepsis, and a time-consuming diagnostic
workup often prevents the early initiation of appropriate
antiinflammatory therapy. Because infections far outnumber cases of systemic-onset JIA as causes of FUO, a
surrogate marker for the latter would be very helpful in
identifying patients with systemic-onset JIA.
The primary goal of our study was to investigate
the potential role of S100A12 in the differential diagnosis of systemic-onset JIA versus acute, severe systemic
infections and childhood leukemias. With the measurement of serum levels of S100A12, a diagnostic tool with
high sensitivity and specificity for the early diagnosis of
systemic-onset JIA can now be added to the existing
laboratory arsenal. The positive likelihood ratios between 6.0 and 11.0 or higher to discriminate between
systemic-onset JIA and other causes of FUO and a
clearly increased posttest probability make determination of serum levels of S100A12 a useful diagnostic tool
(Table 2) (25).
Interestingly, S100A12 serum concentrations in
patients with FMF and those with systemic-onset JIA
are comparable; therefore, differentiation between these
2 diseases via S100A12 measurement is not possible.
However, FMF can easily be distinguished by other
means such as family history and genetic testing, and the
general therapeutic decision against antibiotics and in
favor of antiinflammatory treatment would be appropriate for patients with either of these conditions. In
contrast to systemic-onset JIA, fever and symptoms in
patients with FMF typically occur episodically, although
some of the symptoms, such as abdominal pain, serositis,
lymphadenopathy, dermal rash, or arthritis, can be
present in both diseases. The diagnosis is based on the
clinical presentation and ethnic background, with con-
Table 3.
sideration of diagnostic criteria sets, e.g., the Tel
Hashomer criteria (26). In addition, molecular analysis
of mutations in the MEFV gene helps to identify patients
with suggestive FMF (27). Interestingly, serum levels of
S100A12 in the IL-1–driven syndromes NOMID and
MWS are significantly lower than those in systemiconset JIA and FMF. For diagnostic procedures, this may
help rule out 2 rare causes of FUO in patients with
suspected systemic-onset JIA. Even more interestingly,
this fact points to a common pathogenic mechanism for
systemic-onset JIA and FMF that is not present in other
autoinflammatory disorders.
Published data revealed IL-1 as a key cytokine in
systemic-onset JIA. Nevertheless, reports on the usefulness of IL-1Ra treatment are contradictory (28–31);
while Pascual et al (28) observed that 9 of 9 patients
were responsive to IL1-Ra treatment, Lequerre et al
reported a response in fewer than half of the patients in
their study (31). Peripheral blood mononuclear cells
(PBMCs) release high amounts of IL-1 when incubated
with serum from patients with systemic-onset JIA, thus
suggesting that systemic-onset JIA serum contains factors that are responsible for the activation of leukocytes
(28). Interestingly, at the concentrations we observed in
serum from patients with active systemic-onset JIA,
S100A12 can induce expression of proinflammatory
cytokines along with other proinflammatory effects, but
the exact role of S100A12 in systemic-onset JIA is still
unclear (13,32).
The massive overexpression of this phagocytic
protein in patients with FMF or systemic-onset JIA
points to pathogenic mechanisms closely linked to the
S100A12 levels in a variety of inflammatory disorders, as reported in the literature*
Inflammatory disorder
Mean ⫾ SEM
level, ng/ml
No. of
Author, year (ref.)
Systemic-onset JIA
Familial Mediterranean fever
Systemic infections
Muckle-Wells syndrome
Healthy controls
Crohn’s disease
Ulcerative colitis
Kawasaki vasculitis
Giant cell arteritis
Rheumatoid arthritis
7,190 ⫾ 1,340
6,720 ⫾ 2,340
470 ⫾ 80†
720 ⫾ 210†
150 ⫾ 30†
130 ⫾ 30†
45 ⫾ 20†
50 ⫾ 5†
410 ⫾ 90†
470 ⫾ 125†
400 ⫾ 120†
463 ⫾ 125†
100 ⫾ 15†
480 ⫾ 75†
Present study
Present study
Present study
Present study
Present study
Present study
Present study
Present study
Foell et al, 2004 (11)
Foell et al, 2003 (21)
Foell et al, 2003 (21)
Foell et al, 2003 (33)
Foell et al, 2004 (35)
Wittkowski et al, 2007 (36)
* NOMID ⫽ neonatal-onset multisystem inflammatory disease; ALL ⫽ acute lymphoblastic leukemia;
AML ⫽ acute myeloblastic leukemia.
† P ⬍ 0.001 versus active systemic-onset juvenile idiopathic arthritis (JIA).
innate immune system and specifically to the release of
IL-1 and other cytokines during inflammatory responses. The MEFV gene product pyrin, which is expressed in myeloid/monocytic cells, can bind to the
NALP3 inflammasome that induces autocatalysis of
caspase 1 and may exert inhibitory functions. Secretory
pathways, bypassing the classic Golgi route, are responsible for secretion of S100 proteins and IL-1. Aberrations in these alternative pathways could represent the
link between the massive elevation of S100A12 serum
concentrations and the IL-1–driven pathogenic mechanisms in systemic-onset JIA and FMF (30).
Patients with active systemic-onset JIA (prior to
the initiation of antiinflammatory therapies) present
with serum S100A12 concentrations that differ significantly from the levels in other inflammatory disorders
such as nonsystemic forms of JIA, rheumatoid arthritis,
inflammatory bowel disease, giant cell arteritis, and
Kawasaki disease (Table 3) (11,21,33–36). These published results can be compared with the results of this
study, because all of the ELISAs were performed in one
laboratory, and the same internal control sera have been
used in the different studies, allowing for interassay
comparisons. We expand our observations to childhood
leukemias, in which serum concentrations of S100A12
are significantly lower than those in systemic-onset JIA
and FMF. Previous attempts to establish biomarkers for
systemic-onset JIA concentrated on ferritin, the level of
which is elevated and of diagnostic value in adult-onset
Still’s disease but not in systemic-onset JIA (37).
Very recently, gene expression profiles from the
PBMCs of patients with systemic-onset JIA revealed
specific up-regulation of gene transcripts, differentiating
patients with active systemic-onset JIA from those with
inactive disease and those with other inflammatory
conditions. S100A12 was among the genes significantly
up-regulated (38). Using the same technique, Allantaz et
al identified 12 systemic-onset JIA–specific transcripts distinguishing patients with systemic-onset JIA from those
with other febrile conditions, including infections (39).
In contrast to the above-mentioned gene expression
studies, we tried to differentiate patients with systemiconset JIA by means of a serum biomarker. The advantages
of our method in comparison with array technology are
better availability, lower costs, and convenience of sampling. Analyzing cohorts of patients with very rare disease
is associated with some limitations regarding interpretation
of data, due to the relatively low number of individual
patients. Although the differences in serum concentrations
of S100A12 are very impressive, one must keep in mind
that the age distribution between the different cohorts is
not homogeneous, and, especially in the MWS cohort, we
included a considerable number of adults. However, there
are no differences in S100A12 concentrations in patients
older than age 33 years. A second bias in patients with
MWS may be caused by the fact that 17 of the patients
descended from only 7 families, and as a consequence, only
2 different mutations could be studied. Differences between different systemic-onset JIA and FMF phenotypes
or between different MWS mutations are due to statistical
limitations beyond the scope of our study and should be
clarified in future investigations.
In conclusion, S100A12 may be a valuable laboratory biomarker, expanding our arsenal of diagnostic
tools for detecting systemic-onset JIA, which is more
sensitive and specific than other available indicators of
inflammation. Levels of S100A12 help to confirm the
diagnosis of systemic-onset JIA and allow early differentiation from severe systemic infections and several
other inflammatory and malignant disorders.
Recent research suggests a key role of abnormalities in the innate immune system in the pathogenesis of
systemic-onset JIA and other autoinflammatory diseases, and the up-regulation of markers identifying
phagocyte activation, such as S100A12, is consistent with
these findings. The differential up-regulation of phagocytic S100A12 in systemic-onset JIA and FMF, and to a
lesser extent in the cryopyrin-associated periodic syndromes, points to a key role of neutrophil and monocyte
activation in the pathogenesis of at least systemic-onset
JIA and FMF. Further understanding of the pathogenic
mechanisms underlying the autoinflammatory diseases
may allow for more rational therapies in the future.
We thank Melanie Saers and Dorothee Lagemann for
excellent technical assistance.
Dr. Roth had full access to all of the data in the study and
takes responsibility for the integrity of the data and the accuracy of the
data analysis.
Study design. Wittkowski, Frosch, Kuemmerle-Deschner, Roth, Foell.
Acquisition of data. Wittkowski, Frosch, Wulffraat, Kallinich,
Kuemmerle-Deschner, Frühwald, Dassmann.
Analysis and interpretation of data. Wittkowski, Frosch, GoldbachMansky, Kuemmerle-Deschner, Pham, Roth, Foell.
Manuscript preparation. Wittkowski, Frosch, Wulffraat, GoldbachMansky, Roth, Foell.
Statistical analysis. Wittkowski, Foell.
Provision of samples and clinical data. Goldbach-Mansky.
Preparation of specimens. Pham.
1. Petersdorf RG, Beeson PB. Fever of unexplained origin: report on
100 cases. Medicine (Baltimore) 1961;40:1–30.
2. Durack DT, Street AC. Fever of unknown origin: reexamined and
redefined [review]. Curr Clin Top Infect Dis 1991;11:35–51.
3. Arnow PM, Flaherty JP. Fever of unknown origin [review]. Lancet
4. Gaeta GB, Fusco FM, Nardiello S. Fever of unknown origin: a
systematic review of the literature for 1995-2004 [review]. Nucl
Med Commun 2006;27:205–11.
5. Woo P, Wedderburn LR. Juvenile chronic arthritis [review].
Lancet 1998;351:969–73.
6. Schneider R, Laxer RM. Systemic onset juvenile rheumatoid
arthritis [review]. Baillieres Clin Rheumatol 1998;12:245–71.
7. Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome [review]. Nat Clin Pract Rheumatol 2006;2:
8. Jarvis JN. Pathogenesis and mechanisms of inflammation in the
childhood rheumatic diseases [review]. Curr Opin Rheumatol
9. Niki Y, Yamada H, Seki S, Kikuchi T, Takaishi H, Toyama Y, et
al. Macrophage- and neutrophil-dominant arthritis in human
IL-1␣ transgenic mice. J Clin Invest 2001;107:1127–35.
10. Muller K, Herner EB, Stagg A, Bendtzen K, Woo P. Inflammatory
cytokines and cytokine antagonists in whole blood cultures of
patients with systemic juvenile chronic arthritis. Br J Rheumatol
11. Foell D, Wittkowski H, Hammerschmidt I, Wulffraat NM,
Schmeling H, Frosch M, et al. Monitoring neutrophil activation in
juvenile rheumatoid arthritis by S100A12 serum concentrations.
Arthritis Rheum 2004;50:1286–95.
12. Foell D, Wittkowski H, Roth J. Mechanisms of disease: a ‘DAMP’
view of inflammatory arthritis [review]. Nat Clin Pract Rheumatol
13. Wittkowski H, Sturrock A, van Zoelen MA, Viemann D, van der
Poll T, Hoidal JR, et al. Neutrophil-derived S100A12 in acute lung
injury and respiratory distress syndrome. Crit Care Med 2007;35:
14. Xie J, Burz DS, He W, Bronstein IB, Lednev I, Shekhtman A.
Hexameric calgranulin C (S100A12) binds to the receptor for
advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J Biol Chem 2007;282:4218–31.
15. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al.
RAGE mediates a novel proinflammatory axis: a central cell
surface receptor for S100/calgranulin polypeptides. Cell 1999;97:
16. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand
receptor RAGE as a progression factor amplifying immune and
inflammatory responses. J Clin Invest 2001;108:949–55.
17. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and
autoimmune disease [review]. Arthritis Rheum 2004;50:3762–71.
18. Petty RE, Southwood TR, Manners P, Baum J, Glass DN,
Goldenberg J, et al. International League of Associations for
Rheumatology classification of juvenile idiopathic arthritis: second
revision, Edmonton, 2001. J Rheumatol 2004;31:390–2.
19. Ruperto N, Ravelli A, Falcini F, Lepore L, De Sanctis R, Zulian
F, et al, for the Italian Pediatric Rheumatology Study Group.
Performance of the preliminary definition of improvement in
juvenile chronic arthritis patients treated with methotrexate. Ann
Rheum Dis 1998;57:38–41.
20. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT,
Martini A. Preliminary definition of improvement in juvenile
arthritis. Arthritis Rheum 1997;40:1202–9.
21. Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, et
al. Neutrophil derived human S100A12 (EN-RAGE) is strongly
expressed during chronic active inflammatory bowel disease. Gut
Vogl T, Propper C, Hartmann M, Strey A, Strupat K, van den Bos
C, et al. S100A12 is expressed exclusively by granulocytes and acts
independently from MRP8 and MRP14. J Biol Chem 1999;274:
Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW,
Rueffer A, et al. Fecal S100A12 as non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007;56:1706–13.
Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J,
Rubin BI, et al. Neonatal-onset multisystem inflammatory disease
responsive to interleukin-1␤ inhibition. N Engl J Med 2006;355:
American College of Rheumatology Ad Hoc Committee on
Immunologic Testing. Guidelines for immunologic laboratory
testing in the rheumatic diseases: an introduction. Arthritis
Rheum 2002;47:429–33.
Federici L, Rittore-Domingo C, Kone-Paut I, Jorgensen C, Rodiere M, Le Quellec A, et al. A decision tree for genetic diagnosis of
hereditary periodic fever in unselected patients. Ann Rheum Dis
Drenth JP, van der Meer JW. Hereditary periodic fever [review].
N Engl J Med 2001;345:1748–57.
Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of
interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile
idiopathic arthritis and clinical response to IL-1 blockade. J Exp
Med 2005;201:1479–86.
Fitzgerald AA, LeClercq SA, Yan A, Homik JE, Dinarello CA.
Rapid responses to anakinra in patients with refractory adultonset Still’s disease. Arthritis Rheum 2005;52:1794–803.
Dinarello CA. Blocking IL-1 in systemic inflammation [review]. J
Exp Med 2005;201:1355–9.
Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M,
Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra)
treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in
France. Ann Rheum Dis 2008;67:302–8.
Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, Geczy CL.
Proinflammatory properties of the human S100 protein S100A12.
J Leukoc Biol 2001;69:986–94.
Foell D, Ichida F, Vogl T, Yu X, Chen R, Miyawaki T, et al.
S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet
Foell D, Kane D, Bresnihan B, Vogl T, Nacken W, Sorg C, et al.
Expression of the pro-inflammatory protein S100A12 (ENRAGE) in rheumatoid and psoriatic arthritis. Rheumatology
(Oxford) 2003;42:1383–9.
Foell D, Hernandez-Rodriguez J, Sanchez M, Vogl T, Cid MC,
Roth J. Early recruitment of phagocytes contributes to the vascular
inflammation of giant cell arteritis. J Pathol 2004;204:311–6.
Wittkowski H, Foell D, af Klint E, De Rycke L, De Keyser F,
Frosch M, et al. Effects of intra-articular corticosteroids and
anti-TNF therapy on neutrophil activation in rheumatoid arthritis.
Ann Rheum Dis 2007;66:1020–5.
Sobieska M, Fassbender K, Aeschlimann A, Bourgeois P, Mackiewicz S, Muller W. Still’s disease in children and adults: a distinct
pattern of acute-phase proteins. Clin Rheumatol 1998;17:258–60.
Ogilvie EM, Khan A, Hubank M, Kellam P, Woo P. Specific gene
expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum 2007;56:1954–65.
Allantaz F, Chaussabel D, Stichweh D, Bennett L, Allman W,
Mejias A, et al. Blood leukocyte microarrays to diagnose systemic
onset juvenile idiopathic arthritis and follow the response to IL-1
blockade. J Exp Med 2007;204:2131–44.
Без категории
Размер файла
141 Кб
market, s100a12, molecular, causes, feve, systemic, origin, onset, idiopathic, differentiation, arthritis, juvenile, novem, unknown
Пожаловаться на содержимое документа